A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (NCT05726864)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (4 items).
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Presence of tumor mutations where specific therapy is approved
- Known brain metastases
- Use of immunosuppressive drugs
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (28 Sites)
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic Comprehensive Cancer Center — Phoenix, Arizona
- City of Hope — Duarte, California
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California Los Angeles — Los Angeles, California
- University of California, Irvine — Orange, California
- University of Colorado Hospital-Anschutz Cancer Pavillion — Aurora, Colorado
- University of Miami — Coral Gables, Florida
- University of Florida Health Cancer Center — Gainesville, Florida
- Mayo Clinic Comprehensive Cancer Center — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Emory Winship Cancer Institute — Atlanta, Georgia
- University of Iowa — Iowa City, Iowa
- Ochsner Health — New Orleans, Louisiana
- Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Mayo Clinic Comprehensive Cancer Center — Rochester, Minnesota
- Northwell Health — Lake Success, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- New York Presbyterian Weill Cornell Medical Center — New York, New York
- Lehigh Valley Health Network — Allentown, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania
- Sarah Cannon Research Institute — Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.